Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN2841313 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Pim-3 Oncogene (PIM3) (AA 259-288), (C-Term) antibody
- Antibody type
- Polyclonal
- Description
- This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Epitope
- AA 259-288, C-Term
- Antibody clone number
- RB8591
- Vial size
- 80 μL
- Storage
- Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Submitted references PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.
KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA.
Decker S, Finter J, Forde AJ, Kissel S, Schwaller J, Mack TS, Kuhn A, Gray N, Follo M, Jumaa H, Burger M, Zirlik K, Pfeifer D, Miduturu CV, Eibel H, Veelken H, Dierks C
Molecular cancer therapeutics 2014 May;13(5):1231-45
Molecular cancer therapeutics 2014 May;13(5):1231-45
PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
Brault L, Menter T, Obermann EC, Knapp S, Thommen S, Schwaller J, Tzankov A
British journal of cancer 2012 Jul 24;107(3):491-500
British journal of cancer 2012 Jul 24;107(3):491-500
Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.
Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V
Blood 2009 Nov 5;114(19):4150-7
Blood 2009 Nov 5;114(19):4150-7
KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA.
Cheng F, Weidner-Glunde M, Varjosalo M, Rainio EM, Lehtonen A, Schulz TF, Koskinen PJ, Taipale J, Ojala PM
PLoS pathogens 2009 Mar;5(3):e1000324
PLoS pathogens 2009 Mar;5(3):e1000324
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC
